Oramed Pharmaceuticals Inc. (ORMP)
Market Closed
30 Jul, 20:00
$
4. 12
+0.15
+3.7783%
$
168.62M Market Cap
16.21 P/E Ratio
- Div Yield
149,036 Volume
-0.31 Eps
$ 3.97
Previous Close 
Want to track ORMP and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction
Oramed Pharmaceuticals is downgraded from 'Strong Buy' to 'Hold' due to the failed phase 3 trial for ORMD-0801 in Type 2 Diabetes. ORMP pivots to target a subset of T2D patients and transfers its POD Technology to Lifeward, securing a 49.9% stake and potential revenue streams for ReWalk. Strategic investments in biotech and real estate diversify risk, but cash burn and limited liquidity raise near-term funding concerns.
Seekingalpha | 2 months ago
Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback
Oramed remains viable after its flagship product failed FDA trials three years ago. Management identified a responsive patient subset—elderly with low BMI and high baseline HbA1c—prompting a new 60-patient trial. Positive results from ORMP's Chinese partner reinforce the potential for this narrower patient group.
Seekingalpha | 7 months ago
